Novel Insight of N6-Methyladenosine in Cardiovascular System

N6-methyladenosine (m6A) is the most common and abundant internal co-transcriptional modification in eukaryotic RNAs. This modification is catalyzed by m6A methyltransferases, known as “writers”, including <i>METTL3/14</i> and <i>WTAP</i>, and removed by demethylases, or “era...

Full description

Saved in:
Bibliographic Details
Main Authors: Huan Zhang, Wei Lu, Haoyue Tang, Aiqun Chen, Xiaofei Gao, Congfei Zhu, Junjie Zhang
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/2/222
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849718674032689152
author Huan Zhang
Wei Lu
Haoyue Tang
Aiqun Chen
Xiaofei Gao
Congfei Zhu
Junjie Zhang
author_facet Huan Zhang
Wei Lu
Haoyue Tang
Aiqun Chen
Xiaofei Gao
Congfei Zhu
Junjie Zhang
author_sort Huan Zhang
collection DOAJ
description N6-methyladenosine (m6A) is the most common and abundant internal co-transcriptional modification in eukaryotic RNAs. This modification is catalyzed by m6A methyltransferases, known as “writers”, including <i>METTL3/14</i> and <i>WTAP</i>, and removed by demethylases, or “erasers”, such as <i>FTO</i> and <i>ALKBH5</i>. It is recognized by m6A-binding proteins, or “readers”, such as <i>YTHDF1/2/3</i>, <i>YTHDC1/2</i>, <i>IGF2BP1/2/3</i>, and <i>HNRNPA2B1</i>. Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Recent studies indicate that m6A RNA modification plays a critical role in both the physiological and pathological processes involved in the initiation and progression of CVDs. In this review, we will explore how m6A RNA methylation impacts both the normal and disease states of the cardiovascular system. Our focus will be on recent advancements in understanding the biological functions, molecular mechanisms, and regulatory factors of m6A RNA methylation, along with its downstream target genes in various CVDs, such as atherosclerosis, ischemic diseases, metabolic disorders, and heart failure. We propose that the m6A RNA methylation pathway holds promise as a potential therapeutic target in cardiovascular disease.
format Article
id doaj-art-fe1ee3f055d04bbaa0bb9ef58599649c
institution DOAJ
issn 1010-660X
1648-9144
language English
publishDate 2025-01-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-fe1ee3f055d04bbaa0bb9ef58599649c2025-08-20T03:12:19ZengMDPI AGMedicina1010-660X1648-91442025-01-0161222210.3390/medicina61020222Novel Insight of N6-Methyladenosine in Cardiovascular SystemHuan Zhang0Wei Lu1Haoyue Tang2Aiqun Chen3Xiaofei Gao4Congfei Zhu5Junjie Zhang6Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Cardiology, Lianshui County People’s Hospital, Affiliated Hospital of Kangda College, Nanjing Medical University, Huaian 223400, ChinaDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaN6-methyladenosine (m6A) is the most common and abundant internal co-transcriptional modification in eukaryotic RNAs. This modification is catalyzed by m6A methyltransferases, known as “writers”, including <i>METTL3/14</i> and <i>WTAP</i>, and removed by demethylases, or “erasers”, such as <i>FTO</i> and <i>ALKBH5</i>. It is recognized by m6A-binding proteins, or “readers”, such as <i>YTHDF1/2/3</i>, <i>YTHDC1/2</i>, <i>IGF2BP1/2/3</i>, and <i>HNRNPA2B1</i>. Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Recent studies indicate that m6A RNA modification plays a critical role in both the physiological and pathological processes involved in the initiation and progression of CVDs. In this review, we will explore how m6A RNA methylation impacts both the normal and disease states of the cardiovascular system. Our focus will be on recent advancements in understanding the biological functions, molecular mechanisms, and regulatory factors of m6A RNA methylation, along with its downstream target genes in various CVDs, such as atherosclerosis, ischemic diseases, metabolic disorders, and heart failure. We propose that the m6A RNA methylation pathway holds promise as a potential therapeutic target in cardiovascular disease.https://www.mdpi.com/1648-9144/61/2/222N6-methyladenosinecardiovascular systemischemia–hypoxia injuryatherosclerosisheart failure
spellingShingle Huan Zhang
Wei Lu
Haoyue Tang
Aiqun Chen
Xiaofei Gao
Congfei Zhu
Junjie Zhang
Novel Insight of N6-Methyladenosine in Cardiovascular System
Medicina
N6-methyladenosine
cardiovascular system
ischemia–hypoxia injury
atherosclerosis
heart failure
title Novel Insight of N6-Methyladenosine in Cardiovascular System
title_full Novel Insight of N6-Methyladenosine in Cardiovascular System
title_fullStr Novel Insight of N6-Methyladenosine in Cardiovascular System
title_full_unstemmed Novel Insight of N6-Methyladenosine in Cardiovascular System
title_short Novel Insight of N6-Methyladenosine in Cardiovascular System
title_sort novel insight of n6 methyladenosine in cardiovascular system
topic N6-methyladenosine
cardiovascular system
ischemia–hypoxia injury
atherosclerosis
heart failure
url https://www.mdpi.com/1648-9144/61/2/222
work_keys_str_mv AT huanzhang novelinsightofn6methyladenosineincardiovascularsystem
AT weilu novelinsightofn6methyladenosineincardiovascularsystem
AT haoyuetang novelinsightofn6methyladenosineincardiovascularsystem
AT aiqunchen novelinsightofn6methyladenosineincardiovascularsystem
AT xiaofeigao novelinsightofn6methyladenosineincardiovascularsystem
AT congfeizhu novelinsightofn6methyladenosineincardiovascularsystem
AT junjiezhang novelinsightofn6methyladenosineincardiovascularsystem